PLYX (Polaryx Therapeutics) Accounts Payable: $0.85 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics Accounts Payable?

Polaryx Therapeutics PLYX +2.73% 13 Accounts Payable is $0.85 Mil as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Polaryx Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $0.85 Mil.

Polaryx Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($0.50 Mil) to Dec. 2025 ($0.47 Mil) but then increased from Dec. 2025 ($0.47 Mil) to Mar. 2026 ($0.85 Mil).

Polaryx Therapeutics's annual Accounts Payable declined from Dec. 2023 ($0.47 Mil) to Dec. 2024 ($0.07 Mil) but then increased from Dec. 2024 ($0.07 Mil) to Dec. 2025 ($0.47 Mil).

Polaryx Therapeutics Accounts Payable Related Terms

Polaryx Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Accounts Payable Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Accounts Payable
0.47 0.07 0.47

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.16 0.50 0.47 0.85
PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.85 Mil mean?
Polaryx Therapeutics (PLYX) has a Accounts Payable of $0.85 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Accounts Payable too high?
Polaryx Therapeutics' current Accounts Payable is $0.85 Mil. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Accounts Payable compare to GUTS and NTHI?
Polaryx Therapeutics' Accounts Payable of $0.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Accounts Payable is $0.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current Accounts Payable of $0.85 Mil. The current Accounts Payable is $0.85 Mil. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current Accounts Payable is $0.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price